Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOLIPANC: Neoadjuvant NAPOX Chemotherapy Followed by Curative Resection in Hepatic Oligometastatic Pancreatic Adenocarcinoma
2019-002734-37Phase 2Active
- Sponsor
- University of Cologne
- Start
- Oct 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nanoliposomal irinotecan, oxaliplatin, fluorouracil and folinic acid in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC), sponsored by University of Cologne. Primary endpoint: Overall survival after R0/R1 resection (OS-res). Started Oct 2020; status: active.
02
Drugs
nanoliposomal irinotecanoxaliplatinfluorouracilfolinic acid
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on 2019-002734-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002734-37.